ECSP066718A - DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE - Google Patents

DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE

Info

Publication number
ECSP066718A
ECSP066718A EC2006006718A ECSP066718A ECSP066718A EC SP066718 A ECSP066718 A EC SP066718A EC 2006006718 A EC2006006718 A EC 2006006718A EC SP066718 A ECSP066718 A EC SP066718A EC SP066718 A ECSP066718 A EC SP066718A
Authority
EC
Ecuador
Prior art keywords
treatment
pirazolo
pirimidin
amina
derivatives
Prior art date
Application number
EC2006006718A
Other languages
Spanish (es)
Inventor
Pascal Furet
Keiichi Masuya
Guido Bold
Andreas Floersheimer
Patricia Imbach
Joseph Schoepfer
Georg Martiny-Baron
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066718A publication Critical patent/ECSP066718A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invención se refiere al uso de compuestos de pirazolo[1,5-a]pirimidin-7-il-amina y sales de los mismos, en el tratamiento de enfermedades dependientes de quinasa, y para la fabricación de preparaciones farmacéuticas para el tratamiento de estas enfermedades, a compuestos novedosos de pirazolo[1,5-a]pirimidin-7-il-amina, y a un proceso para la preparación de los compuestos novedosos de pirazolo[1,5-a]pirimidin-7-il-amina.The invention relates to the use of pyrazolo [1,5-a] pyrimidin-7-yl-amine compounds and salts thereof, in the treatment of kinase-dependent diseases, and for the manufacture of pharmaceutical preparations for the treatment of these diseases, to novel pyrazolo [1,5-a] pyrimidin-7-yl-amine compounds, and to a process for the preparation of novel pyrazolo [1,5-a] pyrimidin-7-yl-amine compounds.

EC2006006718A 2004-01-22 2006-07-21 DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE ECSP066718A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53822004P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
ECSP066718A true ECSP066718A (en) 2006-10-31

Family

ID=34807167

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006718A ECSP066718A (en) 2004-01-22 2006-07-21 DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE

Country Status (17)

Country Link
EP (1) EP1708710A1 (en)
JP (1) JP2007519662A (en)
KR (1) KR20070009546A (en)
CN (1) CN1909908A (en)
AR (1) AR049769A1 (en)
AU (1) AU2005205915B2 (en)
BR (1) BRPI0507071A (en)
CA (1) CA2552885A1 (en)
EC (1) ECSP066718A (en)
IL (1) IL176737A0 (en)
MA (1) MA28400B1 (en)
NO (1) NO20063758L (en)
PE (1) PE20051089A1 (en)
RU (1) RU2006130003A (en)
TN (1) TNSN06226A1 (en)
TW (1) TW200528103A (en)
WO (1) WO2005070431A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CA2627623C (en) * 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
MX2008008152A (en) 2005-12-23 2008-09-12 Ariad Pharma Inc Bicyclic heteroaryl compounds.
AU2007223865A1 (en) * 2006-03-08 2007-09-13 Novartis Ag Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
GB0606805D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic compounds
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
KR20090073120A (en) * 2006-09-28 2009-07-02 노파르티스 아게 Pyrazolo[1,5-a]pyrimidine derivatives and their therapeutic use
ATE502943T1 (en) 2006-09-29 2011-04-15 Novartis Ag PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
EP1918291A1 (en) * 2006-10-30 2008-05-07 Novartis AG 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
CA2689667A1 (en) * 2007-06-07 2008-12-18 Schering Corporation Synthesis of substituted-3-aminopyrazoles
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
EP2483263B1 (en) 2009-09-30 2018-07-18 Merck Sharp & Dohme Corp. Heterocyclic compounds that are erk inhibitors
UY33227A (en) * 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
KR101856266B1 (en) * 2010-08-09 2018-05-09 가부시키가이샤 에누비 켄코우겡큐쇼 INHIBITOR OF CASEIN KINASE 1δ AND CASEIN KINASE 1ε
WO2012023143A1 (en) 2010-08-19 2012-02-23 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2013077579A1 (en) * 2011-11-25 2013-05-30 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing and treating ophthalmic disorders
CN105906630B (en) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN106588893A (en) * 2016-12-01 2017-04-26 北京万全德众医药生物技术有限公司 Preparation of vilazodone double oxide
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (en) 2018-01-18 2023-05-09 奥瑞生物药品公司 Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors
SG11202006701TA (en) * 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
JP2022500383A (en) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Condensed heterocyclic compound as a RET kinase inhibitor
CN109836428A (en) * 2019-02-27 2019-06-04 华东师范大学 Pyrazoles [4,3-d] pyrimidine derivatives and purposes with immunosuppressive activity
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
AU2020392087A1 (en) 2019-11-25 2022-06-09 Amgen Inc. Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use
WO2023154282A1 (en) * 2022-02-08 2023-08-17 Theras, Inc. Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
CN114751910B (en) * 2022-05-17 2023-02-24 重庆文理学院 Compound capable of inducing cell megalophage death and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (en) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM
US5688949A (en) * 1991-04-22 1997-11-18 Otsuka Pharmaceutical Factory, Inc. Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same
ES2164153T3 (en) * 1994-06-21 2002-02-16 Otsuka Pharma Co Ltd DERIVATIVE OF PIRAZOLO (1,5-A) PYRIMIDINE.
JP3163413B2 (en) * 1994-06-21 2001-05-08 株式会社大塚製薬工場 Painkillers
WO1998010590A1 (en) * 1996-09-02 1998-03-12 Sony Corporation Device and method for transmitting video signal
CN1701074A (en) * 2002-09-04 2005-11-23 先灵公司 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003265901B2 (en) * 2002-09-04 2006-09-14 Pharmacopeia, Inc. Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
MA28400B1 (en) 2007-01-02
PE20051089A1 (en) 2006-01-25
AU2005205915B2 (en) 2009-05-21
JP2007519662A (en) 2007-07-19
KR20070009546A (en) 2007-01-18
EP1708710A1 (en) 2006-10-11
CA2552885A1 (en) 2005-08-04
WO2005070431A1 (en) 2005-08-04
NO20063758L (en) 2006-10-23
RU2006130003A (en) 2008-04-10
IL176737A0 (en) 2006-10-31
TNSN06226A1 (en) 2007-12-03
CN1909908A (en) 2007-02-07
AU2005205915A1 (en) 2005-08-04
TW200528103A (en) 2005-09-01
AR049769A1 (en) 2006-09-06
BRPI0507071A (en) 2007-06-19

Similar Documents

Publication Publication Date Title
ECSP066718A (en) DERIVATIVES OF PIRAZOLO [1,5-A] PIRIMIDIN-7-IL-AMINA FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
ECSP088350A (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES
MX2007005644A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors.
CR8171A (en) PIRROLO DERIVATIVES [3,4-C] PYRAZOL ASSETS AS QUINASA INHIBITORS
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
UY27755A1 (en) NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS.
ATE400573T1 (en) 1H-IMIDAZOCINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
BRPI0519567A2 (en) tricyclic heterocycles, their manufacture and use as pharmaceutical agents
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
CY1109722T1 (en) INTERMEDIATE COMPOUNDS FOR PREPARATION OF TRANS-5-CHLORO-2-METHYL-2,3,3A, 12B-TETRAHYDRO-1H-DIBENZ [2,3: 6,73OXEPINO [4,5-C] PYRROLE
SE0402735D0 (en) Novel compounds
CL2004000889A1 (en) COMPOUNDS DERIVED FROM PIRAZOLO [4,3-d] PYRIMIDINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HYPERTENSION.
NO20071875L (en) Bicyclic amides as kinase inhibitors
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
UY27222A1 (en) PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS
EA201000092A1 (en) TRIPLE-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
SV2005002148A (en) "MODULATING COMPOUNDS OF THE C-KIT ACTIVITY AND USES OF THE SAME"
BRPI0514750A (en) 7-amino-3-phenyl-dihydropyrime [4,5-d] pyrimidinones amide derivatives, their manufacture and use as protein kinase inhibitors
ATE432281T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
CR20110608A (en) DERIVATIVES OF 1H-IMIDAZO- [4,5-C] -QUINOLINONA
CR8546A (en) DERIVATIVES OF 1H-TIENO [2,3c] PIRAZOL USEFUL AS QUINASE INHIBITORS
CY1111921T1 (en) 7- [2- [4- (6-Fluoro-3-methyl-1,2-benzisoxazol-5-yl) -1-piperazinyl] ethyl] -2- (1-propynyl) -7H-pyrazolo- [4, 3-e] - [1,2,4] -Triazolo [1,5-c] PYRIMIDIN-5-AMINE
CY1110666T1 (en) PYRAZOLOPYRIMIDINES SUITABLE FOR CANCER DISEASE TREATMENT